NASDAQ:IMVT

Immunovant Stock Forecast, Price & News

Top-Rated Stocks

$15.48

+0.21 (+1.38 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.12

Now: $15.48▼

$15.49

50-Day Range

$13.08

MA: $15.92▼

$17.17

52-Week Range

$11.80

Now: $15.48▼

$53.75

Volume424,517 shs

Average Volume1.50 million shs

Market Capitalization$1.52 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IMVT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.immunovant.com

Phone917-580-3099

Employees42

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio35.15

Quick Ratio35.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.45 per share

Price / Book10.68

Profitability

EPS (Most Recent Fiscal Year)($1.54)

Net Income$-66,390,000.00

Net MarginsN/A

Return on Equity-34.80%

Return on Assets-32.38%

Miscellaneous

Outstanding Shares97,971,000

Market Cap$1.52 billion

Next Earnings Date7/5/2021 (Estimated)

OptionableNot Optionable

Headlines

7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
April 13, 2021 | finance.yahoo.com

IMVT Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - GlobeNewswire
April 13, 2021 | globenewswire.com

IMVT Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
April 13, 2021 | finance.yahoo.com

FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
April 12, 2021 | finance.yahoo.com

IMVT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
April 12, 2021 | finance.yahoo.com

UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
April 11, 2021 | finance.yahoo.com

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
April 9, 2021 | finance.yahoo.com

Is IMVT Stock A Buy or Sell? - Yahoo Finance
April 8, 2021 | finance.yahoo.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
April 8, 2021 | finance.yahoo.com

Is IMVT Stock A Buy or Sell?
April 8, 2021 | finance.yahoo.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
April 8, 2021 | finance.yahoo.com

APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Yahoo Finance
April 8, 2021 | finance.yahoo.com

UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
April 7, 2021 | finance.yahoo.com

Immunovant Target of Unusually High Options Trading (NASDAQ:IMVT)
April 7, 2021 | americanbankingnews.com

INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
April 7, 2021 | finance.yahoo.com

IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - GlobeNewswire
April 7, 2021 | globenewswire.com

Immunovant (NASDAQ:IMVT) Shares Gap Up to $15.64
April 7, 2021 | americanbankingnews.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.80 out of 5 stars

Medical Sector

152nd out of 2,019 stocks

Biological Products, Except Diagnostic Industry

20th out of 177 stocks

4.5 Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.60, Immunovant has a forecasted upside of 194.6% from its current price of $15.48.
Amount of Analyst Coverage
Immunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.7 Community Rank

Outperform Votes
Immunovant has received 53 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Immunovant has received 19 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Immunovant has received 73.61% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Immunovant and other stocks. Vote “Outperform” if you believe IMVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.24% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
40.21% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to decrease in the coming year, from ($1.23) to ($1.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -12.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -12.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunovant has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$15.48

+0.21 (+1.38 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Immunovant (NASDAQ:IMVT) Frequently Asked Questions

Is Immunovant a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immunovant stock.
View analyst ratings for Immunovant or view top-rated stocks.

What stocks does MarketBeat like better than Immunovant?

Wall Street analysts have given Immunovant a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunovant wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,450,000 shares, an increase of 41.1% from the March 15th total of 4,570,000 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is presently 4.1 days. Currently, 15.9% of the company's stock are short sold.
View Immunovant's Short Interest.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for Immunovant.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings results on Tuesday, February, 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07.
View Immunovant's earnings history.

How has Immunovant's stock price been impacted by COVID-19?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMVT stock has increased by 9.5% and is now trading at $15.48.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for IMVT?

15 equities research analysts have issued 1-year target prices for Immunovant's shares. Their forecasts range from $28.00 to $64.00. On average, they anticipate Immunovant's share price to reach $45.60 in the next year. This suggests a possible upside of 194.6% from the stock's current price.
View analysts' price targets for Immunovant or view top-rated stocks among Wall Street analysts.

Who are Immunovant's key executives?

Immunovant's management team includes the following people:

Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 54, Pay $1.09M)
Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 59, Pay $544.84k)
Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 50)
Dr. Michael J. Elliott MBBS, Ph.D., Chief Scientific Officer (Age 62)
Ms. Lauren Schrier M.B.A., VP of Marketing
Ms. Beverly Paperiello, Sr. VP of Program Strategy, Chief Medical Officer & Chief of Staff
Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
Dr. Ann M. Daus, VP & Head of Global Quality
Dr. Rita Jain, Chief Medical Officer (Age 57)

Who are some of Immunovant's key competitors?

Some companies that are related to Immunovant include Vir Biotechnology (VIR), Kodiak Sciences (KOD), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Allogene Therapeutics (ALLO), Ablynx (ABLYF), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), Bavarian Nordic A/S (BVNRY), Vericel (VCEL), Editas Medicine (EDIT) and Sorrento Therapeutics (SRNE).
View all of IMVT's competitors.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), The Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Immunovant stock include Julia G Butchko and Sciences Ltd Roivant.
View institutional ownership trends for Immunovant.

Which institutional investors are buying Immunovant stock?

IMVT stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Immunovant stock in the last two years include Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant or or view top insider-buying stocks.

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $15.48.

How much money does Immunovant make?

Immunovant has a market capitalization of $1.52 billion. The company earns $-66,390,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Immunovant have?

Immunovant employs 42 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

Where are Immunovant's headquarters?

Immunovant is headquartered at 320 WEST 37TH STREET, NEW YORK NY, 10018.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099.

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here